Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Increased transvascular retention of atherogenic lipoproteins in type 2 diabetes relates to their enhanced proteoglycan binding
Pär Björklund, Jennifer Härdfeldt, Lauri Äikäs, Sara Straniero, Minna Holopainen, Katariina Öörni, Mats Rudling, Bo Angelin
Pär Björklund, Jennifer Härdfeldt, Lauri Äikäs, Sara Straniero, Minna Holopainen, Katariina Öörni, Mats Rudling, Bo Angelin
View: Text | PDF
Research Article Clinical Research Metabolism Vascular biology

Increased transvascular retention of atherogenic lipoproteins in type 2 diabetes relates to their enhanced proteoglycan binding

  • Text
  • PDF
Abstract

Subendothelial retention of cholesterol-rich apolipoprotein-B–containing lipoproteins drives atherosclerotic arterial disease. In peripheral interstitial fluid from patients with type 2 diabetes (T2D), levels of such particles have been shown to be paradoxically reduced relative to those in serum, presumably reflecting their increased retention within the arterial wall. To identify possible mechanisms involved in lipoprotein retention in T2D, we obtained serum and skin blister fluid from such patients and matched controls, together with skin biopsies in a subset of individuals. In T2D, smaller LDL and VLDL remnant particles were more prominent in serum but not in interstitial fluid, reflecting their enhanced vascular entrapment. The interstitial-fluid-to-serum ratio of apolipoprotein-B was 58% lower in T2D than in controls (0.14 versus 0.33), concomitant with increased susceptibility for LDL binding to proteoglycans. The most marked differences were seen in patients with clinically evident cardiovascular disease. The degree of transvascular retention was positively related to the propensity of isolated serum LDL to bind aortic proteoglycans, both in T2D and in controls. Skin unesterified cholesterol levels were higher in patients with T2D relative to healthy controls. With aging, both proteoglycan binding and apparent vascular retention of LDL increased in controls but not in T2D, indicating that these mechanisms may also be relevant for atherogenesis in nondiabetic individuals.

Authors

Pär Björklund, Jennifer Härdfeldt, Lauri Äikäs, Sara Straniero, Minna Holopainen, Katariina Öörni, Mats Rudling, Bo Angelin

×

Figure 4

Isolated LDL lipid species.

Options: View larger image (or click on image) Download as PowerPoint
Isolated LDL lipid species.
LDL particles were isolated, and their lipid...
LDL particles were isolated, and their lipid composition was analyzed using mass spectrometry. (A and B) The total lipid mass and the respective molar percentages (pie graphs) are presented across the lowest and highest 25% of IF:S for apoB for controls (A) and T2D (B). Lowest 25% ratio [Q1], n = 10:8; highest 25% ratio [Q4], n = 10:10 (controls:T2D). P values of unpaired t tests or Mann-Whitney U tests were adjusted for multiple comparisons by Benjamini and Hochberg FDR correction. TG, triglycerides; CE, cholesteryl esters; DAG, diacylglycerols; Cer, ceramides; LPC, lysophosphatidylcholines; PC, phosphatidylcholines; PE, phosphatidylethanolamines; PI, phosphatidylinositols; SM, sphingomyelins.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts